SEC 13F Intelligence

Viking Global Investors LP / 2655787D

Viking Global Investors LP’s Blueprint Medicines Position

Does Viking Global Investors LP own Blueprint Medicines (2655787D)? Not currently — the last reported position was 213.1K shares worth $21M in Q1 2021; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$21M
Q1 2021
Shares
213.1K
% of Portfolio
+0.06%
Quarters Held
10
position exited

Position History 2655787D

Reported value by quarter
Q4 ’18: $65MQ4 ’18Q1 ’19: $53MQ2 ’19: $52MQ2 ’19Q3 ’19: $59MQ4 ’19: $105MQ4 ’19Q1 ’20: $94MQ2 ’20: $127MQ2 ’20Q3 ’20: $133MQ4 ’20: $31MQ4 ’20Q1 ’21: $21Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 2021213.1K$21M+0.06%
Q4 2020272.7K$31M+0.08%
Q3 20201.43M$133M+0.48%
Q2 20201.63M$127M+0.55%
Q1 20201.60M$94M+0.49%
Q4 20191.31M$105M+0.49%
Q3 2019801.6K$59M+0.31%
Q2 2019551.0K$52M+0.23%
Q1 2019658.7K$53M+0.30%
Q4 20181.20M$65M+0.37%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Viking Global Investors LP’s full portfolio or all institutional holders of 2655787D.